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Long-term decline in lung function, utilisation of care and
quality of life in modified GOLD stage 1 COPD
Abstract
BACKGROUND: Little is known about the long-term outcomes of individuals with mild chronic
obstructive pulmonary disease (COPD) as defined by the Global Initiative for Chronic Obstructive Lung
Disease (GOLD). METHODS: A population cohort of 6671 randomly selected adults without asthma
was stratified into categories of modified GOLD-defined COPD (prebronchodilator spirometry). Further
stratification was based on the presence or absence of respiratory symptoms. After 11 years, associations
between baseline categories of COPD and decline in forced expiratory volume in 1 s (FEV(1)),
respiratory care utilisation and quality of life as measured by the SF-36 questionnaire were examined
after controlling for age, sex, smoking and educational status. RESULTS: At baseline, modified GOLD
criteria were met by 610 (9.1%) participants, 519 (85.1%) of whom had stage 1 COPD. At follow-up,
individuals with symptomatic stage 1 COPD (n = 224) had a faster decline in FEV(1) (-9 ml/year (95%
CI -13 to -5)), increased respiratory care utilisation (OR 1.6 (95% CI 1.0 to 2.6)) and a lower quality of
life than asymptomatic subjects with normal lung function (n = 3627, reference group). In contrast,
individuals with asymptomatic stage 1 COPD (n = 295) had no significant differences in FEV(1) decline
(-3 ml/year (95% CI -7 to +1)), respiratory care utilisation (OR 1.05 (95% CI 0.63 to 1.73)) or quality of
life scores compared with the reference group. CONCLUSIONS: In population-based studies,
respiratory symptoms are of major importance for predicting long-term clinical outcomes in subjects
with COPD with mild obstruction. Population studies based on spirometry only may misestimate the
prevalence of clinically relevant COPD.
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ABSTRACT 
 
Background: Little is known on the long term outcomes of individuals with mild COPD, as 
defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). 
Methods: A population cohort of 6671 randomly selected adults without asthma was 
stratified into categories of modified GOLD-defined COPD (pre-bronchodilator spirometry). 
Further stratification was based on the presence or absence of respiratory symptoms. After 11 
years, associations between baseline categories of COPD and FEV1 decline, respiratory care 
utilization, and quality of life as measured by the SF-36 questionnaire, were examined after 
controlling for age, sex, smoking and educational status.  
Results: At baseline, modified GOLD criteria were met by 610 (9.1%) participants from 
whom 519 (85.1%) had stage 1 COPD. At follow-up, individuals with symptomatic stage 1 
COPD (n=224) had faster FEV1 decline (-9 ml/yr [CI95% -13; -5]), increased respiratory care 
utilization (OR 1.6 [CI95% 1.0 ; 2.6]) and lower quality of life compared to asymptomatic 
subjects with normal lung function (n=3627, reference group). By contrast, asymptomatic 
stage 1 COPD subjects (n=295) had no significant differences in FEV1 decline (-3 ml/yr 
[CI95% -7; +1]), respiratory care utilization (OR 1.05 [CI95% 0.63 ;1.73]) or quality of life 
scores when compared to the reference group.  
Conclusions:  In population-based studies, respiratory symptoms are of major importance for 
predicting long-term clinical outcomes in COPD subjects with mild obstruction.  Population 
studies that are based on spirometry only may misestimate the prevalence of clinically 
relevant COPD. 
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INTRODUCTION  
The Global Initiative for Chronic Obstructive Lung Disease (GOLD), updated in 2006, 
distinguishes four categories of chronic obstructive lung disease (COPD) severity based on a 
fixed ratio of forced expiratory volume in one second (FEV1) / forced vital capacity (FVC) 
and the percent predicted FEV1 value.[1]  This classification has been issued to help clinicians 
detect COPD and offer up-to-date therapy to patients; it has been proposed as a research tool 
for international comparisons of COPD prevalence, as well as a common definition in clinical 
trials. Finally, the GOLD classification has been promoted to estimate future health care 
resources as a result of the growing prevalence of the disease.  
Many population studies on the prevalence of COPD rely on airflow obstruction as measured 
by spirometry, without requirement for reporting symptom, exposure to noxious particles or 
fumes. [2-9] During the period 1990-2004, Halbert et al found a pooled prevalence of 
spirometry-defined COPD of 9.2% whereas the prevalence of physician-diagnosed or self-
reported COPD were lower.[10] More recently the Burden Of Obstructive Lung Disease 
(BOLD) Initiative reported a prevalence of GOLD 1 COPD varying between 1.4% 
(Philippines) and 15.5% (Austria).[8] Also, in population studies, GOLD 1 COPD is 
frequently the most prevalent stage of the disease. For example, in 5 Latin American cities, 
the prevalence of GOLD 1 COPD ranged from 5.2% to 12.5% whereas stage 2 or higher was 
uniformly lower (2.6% to 7.1%).[9]   
The impact on mortality, health care utilization and quality of life of GOLD stage 2-4 COPD 
which include subjects with abnormal FEV1/FVC ratio and FEV1 below 80%, 50% and 30% 
respectively, is well recognized.[11, 12]  In contrast, the clinical significance of GOLD 1 
COPD, that encompasses subjects with FEV1/FVC <70% and FEV1 ≥80% predicted is much 
less clear.  
Two population-based studies have specifically addressed the question of mortality in COPD 
according to the GOLD classification.[13, 14]  Both showed that GOLD 1 COPD was 
associated with a slightly increased mortality, but only when these subjects had symptoms of 
chronic bronchitis. Data on the association between GOLD 1 COPD and health care 
utilization are scarce. The net risk for COPD-related hospitalization was increased in subjects 
with GOLD 1 COPD in one report. However, these data suggested that this risk was not 
higher than in chronic bronchitis without obstruction.[15] 
Since subjects with mild GOLD 1 COPD generally constitute more than half of the 
individuals with COPD in population studies, it is crucial to have more information about 
them on clinically relevant outcomes.  This could help provide accurate estimates of health 
care need and risk prediction for individuals with mild, GOLD-defined abnormal lung 
function.  
Therefore, the aim of this study was to compare the long-term FEV1 decline, respiratory care 
utilization and quality of life (QoL) between individuals with symptomatic or asymptomatic 
stage 1 COPD. 
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METHODS  
 
Study population: 
The SAPALDIA cohort (Swiss Study on Air Pollution and Lung Diseases in Adults) 
(n=9651), a random sample of the Swiss population, was initially assembled in 1991 to 
address the effect of air pollution on respiratory health. Detailed descriptions of the 
SAPALDIA study are published elsewhere.[16, 17] Briefly, individuals, aged 18-60 years, 
were randomly drawn from local registries of 8 areas chosen to represent cultural and 
geographical diversity of Switzerland (Geneva, Basel, Lugano, Aarau, Wald, Payerne, Davos 
and Montana). Of those, 8876 had interpretable spirometry and provided information about 
respiratory symptoms in 1991. For this study, subjects who reported physician-diagnosed 
asthma at SAPALDIA 1 (1991) were excluded (n=594). (Figure 1).  Out of 8282 eligible 
subjects from the 1991 sample, the follow up study in 2002 included 6671 subjects 
(participation rate 80.5%). In the present analysis, 5498 (66.4%) underwent pulmonary 
function tests, 6670 (80.5%) reported health care utilization, and 5000 (60.4%) filled in the 
Short-Form 36 questionnaire (SF-36).  Ethics committee approvals were obtained from the 
participating centers and from the Swiss Academy of Medical Science.  
 
Pulmonary function tests and symptoms assessment 
Pulmonary function tests were performed according to the American Thoracic Society 
Standards, in 1991 and 2002, using the same spirometers (SensorMedics 2200 SP Yorba 
Linda, CA, USA). The longitudinal validity of the spirometers was also verified.[18]  Forced 
expiratory maneuver was obtained without bronchodilators. We calculated the predicted 
values for FEV1 and FVC using the 1993 European Respiratory Society equation.[19] The 
modified-GOLD classification was adapted to group subjects with FEV1/FVC <0.7 and pre-
bronchodilator FEV1 ≥80% into the stage 1 COPD category and those with FEV1 < 80% into a 
single stage 2-4 category. Respiratory symptoms were considered present if subjects reported 
at baseline examination (1991) chronic cough, phlegm or shortness of breath while walking. 
Respiratory questionnaires are detailed in the online supplement 
(http://thorax.bmj.com/supplemental). Finally, the cohort (n=6671) was stratified on the basis 
of the GOLD classification and the presence/absence of respiratory symptoms at the first 
examination (SAPALDIA 1 [1991]).  
 
Yearly FEV1 decline was calculated by subtracting the first to the second FEV1 absolute 
value, divided by the time between the two measurements. 
 
Respiratory care utilization 
Any report to the interviewer of inhaler use, emergency room visit or hospitalization due to 
respiratory problems, ambulatory visit to a chest physician, to an asthma specialist or to a 
primary care provider for respiratory problems during the year preceding the follow up survey 
(SAPALDIA 2 [2002]) was considered as “respiratory care utilization”.  
 
Quality of Life 
The Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) was filled 
in at the follow up examination (2002). As Switzerland is a multilingual country, German, 
French or Italian versions were administered.[20-22] The Physical Component Summary 
(PCS) and the Mental Component Summary (MCS) were derived from the 
questionnaires.[23] 
 
Covariates 
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Nationality, education level, smoking status (never, former, current), and lifetime smoking 
(pack/yr) were derived from the main health inventory questionnaires. Height, weight and 
body-mass index (BMI) were recorded immediately before the pulmonary function 
testing.[17] 
 
Statistical analysis 
Outcomes of interest were mean FEV1 decline per year, respiratory care utilization and SF-36 
summary scores. Main predictors of interest were the modified GOLD categories stratified by 
presence or absence of respiratory symptoms. We developed mixed linear and logistic 
regression models with adjustment for age, sex, baseline FEV1, smoking status, lifetime 
smoking, baseline BMI (kg/m2), weight change, education level, nationality and study area 
(random effect).  
To address the issue of missing responses, we fitted a logistic regression model to predict 
probability of non-participation using baseline variables. As a sensitivity analysis, regression 
models were rerun while weighting each observation by the inverse of the respective subject’s 
propensity of participation.. We performed additional analyses without excluding those with 
physician-diagnosed asthma in 1991. The association between the specific outcome 
“emergency room visits or hospitalization due to respiratory problems” and modified GOLD 
and symptom categories was also examined.  Finally, the effect of smoking persistence or 
cessation between the 2 surveys was assessed.   
All analyses were conducted with Stata 10.0 version (StataCorp, 4905 Lakeway Drive, 
College Station, Texas 77845 USA). 
 
RESULTS  
Characteristics of the SAPALDIA cohort and of participants 
Table A (http://thorax.bmj.com/supplemental) displays the characteristics of the cohort at 
SAPALDIA 1 [1991]. Overall, 610 (9.1%) subjects had a FEV1/FVC ratio <0.7 and were 
classified as COPD according to the pre-bronchodilator GOLD-defined fixed ratio. Among 
those, 519 (85.1%) had a FEV1 ≥80% of the predicted value and were classified as stage 1 
COPD. More than half of subjects classified as stage 1 COPD were free of respiratory 
symptoms (n=295; 56.8%). Overall, individuals with modified GOLD-defined obstruction 
were older, more frequently male and ever-smoker.  
Compared with participants, non-participants at SAPALDIA 2 were more likely to be 
younger, non-Swiss citizens, current smokers, obese and to have respiratory symptoms at 
SAPALDIA 1. More information on non-participants is given in the online supplement. 
(Table B & C http://thorax.bmj.com/supplemental).  
FEV1 decline 
Net annual FEV1 decline over 11 years was 35 ml/yr (SD 29) for subjects with normal lung 
function (n=4997), 40 ml/yr (SD 37) for stage 1 COPD (n=430) and 28 ml/yr (SD 40) for 
stage 2-4 COPD (n=71) (p<0.01). Table 1 summarizes unadjusted FEV1 decline by modified 
GOLD and by symptom categories. Compared to asymptomatic subjects with normal lung 
function (reference group), the unadjusted FEV1 decline was faster only for symptomatic 
subjects with normal lung function (p=0.001) and for symptomatic stage 1 COPD (p<0.001) 
categories. Within stage 1 COPD, a trend toward faster FEV1 decline was measured before 
adjustment for symptomatic [- 44 ml (SD 38)] versus asymptomatic subjects [- 38 ml (SD 
36)] (p=0.11). 
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Table 1: Unadjusted FEV1 decline over 11 years, respiratory care utilization and SF-36 summary score at follow up 
(SAPALDIA 2 [2002]), stratified by modified GOLD† and symptom categories at SAPALDIA 1 (1991)   
 
 
FEV1 
decline 
(ml/year) 
mean, (SD) 
n= 5498 P§ 
Respiratory 
care 
utilization, 
% [n] 
n=6670 P ‡ 
PCS mean, 
(SD) 
 
n= 5000 P§ 
MCS 
mean, 
(SD) 
 
n=5000 P§ 
No symptom,    -34 (29)  7.3 [265/3626]  53.1 (6.7)  51.5 (7.7)  Normal lung 
function† 
with symptom* -37 (30) <0.01 14.7 [358/2434] <0.01 50.6 (9.1) <0.01 48.7 (9.4) <0.01 
  
        
No symptom     -38 (36) 0.08 8.1 
 [24/295] 0.60 51.2 (8.2) <0.01 52.5 (7.6) 0.05 Stage 1 COPD† 
with symptom* -44 (38) <0.01 12.5  [28/224] <0.01 48.7 (10.8) <0.01 48.9 (10.1) <0.01 
  
        
No symptom       -25 (43) 0.33 23.4 [7/30] <0.01 51.4 (4.4) 0.09 53.9 (6.3) 0.08 Stage 2-4 
COPD† 
with symptom*   -29 (39) 0.38 34.4  [21/61] <0.01 44.2 (12.1) <0.01 50.5 (9.8) 0.54 
†: pre-bronchodilator spirometry. § t-test for unequal variances for comparison to the reference category: “Normal lung function, no symptom”  
*: report of chronic cough or phlegm or shortness of breath while walking. see online supplement for detailed questions. 
‡ χ2 test for comparison to the reference category: “Normal lung function, no symptom”    
PCS = Physical Component Summary of SF-36 
MCS = Mental Component Summary of SF-36 
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Figure 2 depicts the results of the multivariate analysis of mean annual FEV1 decline over 11 
years by categories of modified GOLD and stratified by the presence of symptoms at 
SAPALDIA 1 (1991). Presence of symptoms in subjects with normal lung function at 
baseline was associated with significant difference in FEV1 decline compared to the reference 
group [-4 ml/yr (CI95% -5 ; -2)]. Likewise, symptomatic stage 1 COPD subjects exhibited an 
additional FEV1 loss of -9 ml/yr (CI95% -13 ; -5) compared to the reference group. In 
contrast, asymptomatic subjects with stage 1 COPD and the reference group had similar FEV1 
decline [-3 ml/yr (CI95% -7 ; +1)]. Moreover, a significant difference in FEV1 decline was 
observed when comparing asymptomatic and symptomatic subjects within the stage 1 COPD 
category [- 6 ml/yr (CI 95% -11; -1)]. stage 2-4 COPD subjects showed consistently greater 
FEV1 losses compared to the reference group.  
 
Respiratory care utilization 
Unadjusted differences in the report of respiratory care utilization at SAPALDIA 2 (2002) 
between the subjects’ categories are summarized in Table 1. Overall, 10.3% of individuals 
with normal lung function at SAPALDIA 1 (1991) reported utilization of respiratory care 
during the year preceding the SAPALDIA 2 survey, compared to 10.0% (p=0.85) and 30.8% 
(p<0.01) of individuals with stage 1 and stage 2-4 COPD respectively.  
 
Figure 3 shows the results of the multivariate analysis stratified by GOLD categories and 
presence of symptoms. Symptomatic subjects with normal lung function were more likely to 
report respiratory care utilization (OR 1.9 [CI95% 1.6; 2.3]). Asymptomatic subjects with 
stage 1 COPD reported similar rates of respiratory care utilization as the reference category 
(OR 1.05 [CI95% 0.63; 1.73]), whereas symptomatic stage 1 COPD subjects had increased 
rates (OR 1.62 [CI95% 1.10; 2.61]). Finally, the strongest predictors for reporting respiratory 
care utilization were having stage 2-4 COPD without or with symptoms (OR 4.05 [CI95% 
1.59 ; 10.30] and 5.67 [CI95% 2.86; 11.22] respectively). Detailed results are accessible in the 
online supplement (Table D http://thorax.bmj.com/supplemental).    
 
Quality of life scores 
The unadjusted SF-36 summary scores are displayed in Table 1. GOLD defined COPD was 
associated with lower physical QoL.  In subjects with normal lung function, stage 1 and stage 
2-4 COPD, PCS scores were 52 (SD 8), 50 (SD 9) and 47 (SD 11), respectively (p<0.01). 
MCS scores were not different between the three above-mentioned categories [mean 50 (SD 
9)] (p= 0.17). 
 
After controlling for covariates, only those with symptoms at baseline had significantly lower 
PCS scores compared to asymptomatic subjects with normal lung function irrespective of the 
modified GOLD classification status (Figure 4). Compared to reference category, the PCS 
were lower for symptomatic subjects with stage 2-4 COPD (-5.2 points), for symptomatic 
stage 1 COPD (-1.6 points) and symptomatic individuals with normal lung function (-1.6 
points). In contrast, those who were free of symptoms at baseline reported QoL scores close 
to the reference category. In parallel with lung function decline and respiratory care 
utilization, differences were present in PCS or MCS scores between asymptomatic and 
symptomatic stage 1 COPD subjects (PCS difference -1.4 [CI95% -3.0  ; +0.2];  MCS 
difference -3.2 [CI95% -4.9 ; -1.4]). 
 
Sensitivity analyses 
In the weighted data analysis, the associations between FEV1 decline, respiratory care 
utilization, SF-36 summary scores and GOLD and symptom categories were robust and 
unchanged.  
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When including subjects with physician-diagnosed asthma in the analysis, we found that 
estimates of FEV1 decline for GOLD and symptom categories were close to those using the 
original cohort. Moreover in this analysis, the difference in FEV1 decline between 
asymptomatic and symptomatic stage 1 COPD subjects was larger (-8 ml/yr [CI95% -13 ; -3]) 
than in the analysis excluding asthmatics. (table E, (http://thorax.bmj.com/supplemental).The 
analysis centered on emergency room visit / hospitalisations for respiratory problems, as a 
specific respiratory care utilization outcome, showed that asymptomatic stage 1 COPD 
subjects had a similar rate of event than asymptomatic subjects with normal lung function 
(OR 0.83 [CI95% 0.19 – 3.71]). (Table F, http://thorax.bmj.com/supplemental). As expected, 
smoking persistence was associated with faster FEV1 decline in stage 1 COPD compared to 
persistent smokers with normal lung function. However, within persistent smokers with stage 
1 COPD, FEV1 decline was not significantly faster for symptomatic subjects when compared 
with asymptomatic subjects (data not shown).  Stage 1 COPD quitters had similar long-term 
outcomes compared to quitters with normal lung function. Finally, the interaction between 
amount of smoking (pack years between SAPALDIA 1 and 2) and GOLD-symptom 
categories, added to the multivariate models for asymptomatic and symptomatic mild COPD 
subjects, was not significant for FEV1 decline (p=0.52), QoL (PCS, p=0.23; MCS, p=0.68) 
and respiratory care use (p=0.19). 
 
DISCUSSION 
In this population-based cohort, we found that the presence or absence of respiratory 
symptoms at baseline in adults with stage 1 COPD significantly modified long-term FEV1 
decline, respiratory care utilization patterns and HRQoL scores. Symptomatic stage 1 
COPD had long-term faster functional decline, increased respiratory care utilization and lower 
health-related quality of life compared to asymptomatic subjects with normal lung function, 
whereas asymptomatic stage 1 subjects were similar to the reference group regarding these 
outcomes. 
In contrast, subjects with stage 2-4 COPD had worse long term outcomes, independently of 
the presence or absence of symptoms at baseline.  
Lung function decline 
Historically, accelerated lung function decline has been recognized as a hallmark of 
COPD.[24] In the present study, net FEV1 decline in subjects with stage 1 COPD, taken 
together, was faster compared to subjects with normal lung function. However, we found that 
FEV1 decline within stage 1 COPD subjects was statistically different in relation to absence or 
presence of respiratory symptoms. Those with stage 1 COPD and symptoms had a 
significantly faster FEV1 decline compared to the asymptomatic subjects with normal 
spirometry. On the other hand, asymptomatic subjects labelled as stage 1 COPD had trend 
toward faster FEV1 decline, which was not statistically significant. Symptoms might be linked 
to a remodelling process of higher intensity in the airways and can represent as a 
consequence, a prognostic marker of functional impairment.[25] This hypothesis is consistent 
with the observation that chronic bronchitis, without obstruction, is a risk factor for 
developing COPD[26, 27]. For example, Lindberg et al reported a 2 to 3-fold increase in the 
cumulative 10-year incidence of COPD in the presence of respiratory symptoms.[26] This 
was also noticed by de Marco et al in a longitudinal population study: the risk of COPD was 
higher for those with persistent bronchitis symptoms compared to asymptomatic subjects 
(relative risk 2.9 [CI95% 1.4 ; 5.8]).[27] However, to our knowledge, this is the first report to 
show that respiratory symptoms, as defined by chronic cough, phlegm or shortness of breath 
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by walking predict accelerated lung function decline and other clinically relevant outcomes in 
stage 1 COPD subjects.  
Respiratory care utilization 
Symptomatic individuals with stage 1 COPD at SAPALDIA 1 were 1.6-times more likely to 
report respiratory care utilization, whereas those free of respiratory symptoms had similar 
rates compared to asymptomatic subjects with normal lung function. In the sensitivity 
analysis,  results were unchanged when respiratory care utilization was strictly defined by 
emergency room visit or hospitalization for respiratory problems. The odds ratio of 
respiratory care utilization was also increased for symptomatic subjects with normal lung 
function. To date, no other population study specifically reported long-term utilization of 
respiratory care in subjects with stage 1 COPD. The similar rate of respiratory care utilization 
for subjects with asymptomatic stage 1 COPD and those with normal lung function could be 
interpreted in several ways: individuals labelled as stage 1 COPD may represent a normal 
variant of lung function, with little potential for developing clinical disease.  Another 
interpretation could be that a larger cohort or a follow-up longer than 11 year may have more 
power to observe differences in terms of respiratory care utilization. 
Individuals with stage 2-4 COPD at baseline had up to a 6-fold higher risk of respiratory care 
utilization later. This last result is in line with published literature.  A case-control study 
showed that utilization of respiratory care was 12-times higher for those with physician-
diagnosed COPD compared to controls.[28]  Similarly, a population study reported a 5 to 15-
fold higher risk of hospitalization for stage 2-4 COPD.[29]  In another cohort of patients with 
severe to very severe COPD, lower lung function and QoL were independent predictors of 
hospitalizations or emergency department visits.[30]   
Quality of Life 
In parallel with respiratory care utilization, asymptomatic subjects with stage 1 COPD and 
those with normal lung function are similar in terms of QoL scores. These results are in line 
with a previous study: Antonelli-Incalzi found that stage 1 COPD did not correspond to 
meaningful alteration in QoL.[31]  This same study suggested that the deterioration of the 
health status was possibly due to respiratory symptoms, which is also indicated by our results.  
Overall, symptomatic subjects with normal lung function, stage 1 or stage 2-4 COPD had 
significantly lower physical and mental health scores in the present cohort.  
Quality of life in COPD has been mainly assessed in patients recruited from primary care 
clinics. [12, 32] Compared to these studies, the physical and mental health scores of our 
subjects were higher, even for stage 2/4 COPD. This is not unexpected as our subjects were 
sampled from the general population, and were not primarily identified as patients.   
 
Strengths and limitations  
Strengths of our study are the size of the cohort, which is a representative sample of the Swiss 
population. For example, in terms of BMI or smoking behaviour, the SAPALDIA sample 
compares with other population studies in Europe and with the Swiss population, thus 
supporting external validity [33]. Participation rate at follow up was high. We were able to 
use detailed information on confounding factors such as lifetime smoking, nationality or 
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education. Nevertheless some residual confounding related to socio-demographic variables 
may still be present. Another strength is the rigorous quality control of spirometric 
records.[16-18]   
Limitations are related to the absence of post bronchodilator spirometry and repeated lung 
function measures, which may result in overdiagnosis of mild COPD. The potential of 
misclassification was recently evaluated at 27% by Johannessen et al in a population study in 
Norway using bronchodilation and was higher for younger subjects and never-smokers.[34]  
Another Korean study reported a higher misclassification risk of 52%. [6] However, the effect 
of this potential misclassification is in part reduced in our study since we excluded asthmatics 
unlike the studies in Norway or Korea.  In addition, our subjects with modified stage 1 COPD 
were on average older than the reference group and less likely to be never smokers.. Another 
limitation may be due to the differential loss to follow-up. Like in other cohort studies, 
subjects with lower education level and worse lung function were more likely to be non-
participant at follow-up. [35]  Such a bias would actually decrease the differences between the 
GOLD and symptom categories compared to the reference group. It should also be noticed 
that in our cohort, loss to follow-up in the stage 1 COPD category was close to loss to follow-
up in the reference group. In addition, the weighted sensitivity analyses showed that our 
results were only marginally affected by missing data.  
Finally, we noted that the subgroup of subjects with stage 1 COPD who were persistent 
smokers between both surveys had accelerated FEV1 decline without significant difference 
between symptomatic and asymptomatic individuals. Therefore the presence or absence of 
symptoms might not be such a strong determinant of FEV1 decline in persistent smokers as it 
is in other subjects. However, lack of power in these subgroups analysis requires caution. As a 
whole, our results indicate that different biological mechanisms may interact in symptomatic 
and asymptomatic subjects with mild COPD. 
 
Conclusions 
In summary, we show that in a population-based study, symptomatic and asymptomatic adults 
with stage 1 COPD have contrasted long term FEV1 decline, respiratory care utilization and 
QoL scores. In addition, respiratory symptoms at baseline in subjects without GOLD-defined 
COPD come out as predictors of these outcomes. This suggests that population cross-
sectional studies that are based only on spirometry may misestimate the prevalence of 
clinically relevant COPD. The risk of COPD misclassification is likely increased by the 
absence of bronchodilation to define airways obstruction . The heterogeneity of subjects with 
spirometry-defined stage 1 COPD should be addressed in future population studies in order to 
predict their long term clinical outcomes and to estimate the public health needs related to 
COPD. 
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COPD: Long Term Lung Function Decline, Utilization of Care and Quality of Life in 
Modified GOLD stage 1 
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Respiratory questionnaires at SAPALDIA 1 
Subjects were considered symptomatic if they answered yes to one of the following questions: 
Chronic cough:   
“Do you usually cough first thing in the morning?” or  
 “Do you usually cough during the day, or at night?” or  
“Do you cough like this on most days for as much as 3 months each year?” 
Chronic phlegm:  
“Do you usually bring up phlegm from your chest first thing in the morning?” or  
“Do you bring up phlegm like this on most days for as much as 3 months each year?” or  
“Do you usually bring up any phlegm from your chest during the day, or at night?” 
Chronic dyspnea:  
“Are you troubled by shortness of breath when hurrying on level ground or walking up a slight 
hill?” or 
“Do you get short of breath walking with other people of your own age on level ground?” or 
“Do you have to stop for breath when walking at your own pace on level ground? 
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Table A (online supplement):   Demographic characteristics of subjects, stratified by modified GOLD† and symptom categories at baseline 
(SAPALDIA 1 [1991]) 
SAPALDIA 1 Characteristics 
n=6671 
 Normal lung function† 
n=6061 
Stage 1 COPD† 
n=519 
Stage 2-4 COPD† 
n=91 
 No symptom 
n=3627 
With 
symptom* 
n=2434 
No symptom 
n=295  
With 
symptom* 
n=224 
No symptom 
n=30 
With 
symptom* 
n=61 
Age, mean (SD) 39.4 (11.4) 41.8 (11.4) 48.2 (11.4) 48.7 (9.7) 45.9 (10.2) 49.8 (10.2) 
Male, % 51.6 36.5 67.5 54.0 73.3 62.3 
BMI, kg/m2 (SD) 23.4 (3.4) 24.1 (4.1) 24.8 (3.1) 25.1 (3.6) 24.9 (3.3) 25.2 (4.4) 
Obesity (BMI ≥30 kg/m2  ), % [n]  4.1 [147] 7.9 [192]  7.1 [21]  8.5 [19]  10.0 [3] 11.5 [7]  
Swiss citizenship, % [n]  88.0 [3193] 83.6 [2034] 88.1  [258] 86.2  [193] 87.0 [26] 88.5 [54] 
Low education, % [n] 5.6 [202] 10.7 [261] 6.4  [19] 15.2 [34] 10.0 [3] 14.8 [5] 
Smoking status       
Current smoker, % [n] 26.0 [943] 37.5 [913] 37.5 [110] 49.1 [110] 36.7 [11] 52.5 [32] 
Former smoker, % [n] 23.1 [839] 20.7 [504] 27.3 [80] 23.2 [52] 36.7 [11] 26.2 [16] 
Never smoker, % [n] 50.8 [1843] 41.8 [1017] 35.2 [103] 27.7 [62] 26.7 [8] 21.3 [13] 
Lifetime smoking (pack-year), mean (SD) in 
ever smoker 15.0 (15) 18 (19) 24 (20) 32 (25)  21 (13) 41 (29) 
Pulmonary function tests       
FEV1, (% predicted), mean (SD)  109 (13) 108 (14) 101 (12) 99 (12) 71 (7) 68 (9) 
FEV1/FVC ratio, mean (SD) 81 (6) 81 (6) 67 (3) 66 (4) 59 (8) 58 (9) 
Restrictive pattern‡, % [n] 0.7 [25]  1.6 [38]  - - - - 
Respiratory symptoms        
Chronic cough, % - 8.8 - 15.2 - 23.0 
Chronic phlegm, % - 13.4 - 17.9 - 23.0 
Chronic shortness of breath, % - 91.5 - 88.0 - 88.5 
Chronic bronchitis§, % - 19.0 - 29.5 - 34.4 
BMI: Body-mass Index; FEV1: Forced Expiratory Volume in 1 sec; FVC: Forced Vital Capacity. †: pre-bronchodilator spirometry 
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*: report of chronic cough or phlegm or shortness of breath while walking, see online supplement for detailed questions. ‡: FEV1/FVC ≥0.7 & 
FVC<80% predicted. 
 
§: chronic cough or phlegm 
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Table B (online supplement):  Odds ratio* of non participation to the pulmonary function 
test (PFTs), the respiratory care collection forms and the SF-36 questionnaires.  
 
 
OR* of no PFTs at 
follow up (CI 95%) 
 
 
 
Non-participants 
n=2784/8282 
OR* of no response 
to respiratory care 
questions at follow 
up (CI 95%) 
 
Non-participants 
n=1612/8282 
OR* of no response 
to SF-36 
questionnaire at 
follow up (CI 95%) 
 
Non-participants 
n=3282/8282 
Age categories    
55+ 1 1 1 
45 - 55 0.8 (0.6 – 1.0) 0.8 (0.7 – 1.1) 0.9 (0.7 – 1.2)  
35 - 45 0.8 (0.6 – 1.1) 0.9 (0.7 – 1.1) 1.0 (0.8  – 1.4) 
25 -35 1.0 (0.7 – 1.3) 1.0 (0.8 – 1.2) 1.1 (0.8  –1.4) 
<25 1.2 (0.8 -1.6) 1.4 (1.1 -1.8) 1.4 (1.0  – 2.0) 
Gender    
Male 1 1 1 
Female 1.0 (0.9 – 1.2) 0.9 (0.7 – 1.1) 1.1 (0.9  –  1.3) 
Nationality    
Swiss 1 1 1 
Non-Swiss  2.4 (2.0 – 3.0) 2.9 (2.5 – 3.4) 2.7 (2.2  – 3.3) 
Smoking status    
Never smoker 1 1 1 
Former smoker 1.2 (0.9 – 1.5) 1.3 (1.1 – 1.5) 1.2 (1.0  –  1.4) 
Current smoker 1.5 (1.3 – 1.8) 1.5 (1.3 – 1.8) 1.5 (1.3  –  1.8) 
Body mass index     
Normal (<24.9 kg/m2) 1 1 1 
Overweight (25 to 29.9 
kg/m2) 1.2 (1.0 – 1.5) 1.1 (0.8 – 1.4) 1.1 (0.9  –  1.4) 
Obese (>30 kg/m2) 1.8 (1.3 – 2.5) 1.6 (1.0 – 2.6) 1.8 (1.3  – 2.5) 
GOLD and symptom 
categories    
Normal lung function† 1 1 1 
Stage 1† 0.9 (0.6 – 1.2) 1.1 (0.8 – 1.4) 1.0 (0.7  – 1.3) 
Stage 2-4 † 1.3 (0.7 – 2.4) 1.6 (1.0 – 2.6) 2.0 (0.7  – 1.3) 
 
   
No respiratory symptoms‡ 1 1 1 
Respiratory symptoms‡ 1.2 (1.0 – 1.4) 1.2 (1.1 –  1.4) 1.1 (0.9  –  1.4) 
 *Multivariate logistic regression model controlling for the above-mentioned variable and the 
study area (random effect); †: pre-bronchodilator spirometry 
‡: one or more symptoms = report of chronic cough or phlegm or shortness of breath while 
walking 
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Table C (online supplement):  Participation rate by modified GOLD† and symptom categories at SAPALDIA 1 (1991) 
n=6671 
 
Potential 
participants 
Pulmonary function 
tests,  
n, (%) 
Respiratory care 
utilization data, 
 n, (%) 
SF-36 questionnaire, 
n, (%) 
All, n, (%)  8282 5498 (66.4) 6670 (80.5) 5000 (60.4) 
No symptom,    4377 3034 (69.3) 3626 (82.8) 2779 (63.5) Normal lung 
function† with symptom‡  3089 1963 (63.6) 2434 (78.8) 1783 (57.7) 
  
 
   
No symptom     363 257 (70.8) 295 (81.3) 222 (61.2) Stage 1 COPD† 
with symptom‡    319 173 (54.2) 224 (70.2) 156 (48.9) 
  
 
   
No symptom       37 25 (67.6) 30 (81.1) 22 (59.5) Stage 2-4 COPD† 
with symptom‡    97 46 (47.4) 61 (62.9) 38 (39.2) 
†: pre-bronchodilator spirometry, ‡: one or more symptoms = report of chronic cough or phlegm or shortness of breath while walking 
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Table D: Unadjusted and adjusted long-term outcomes associated with modified GOLD† 
and symptom categories 
  FEV1 decline (ml/year)  
 
 
Unadjusted, 
mean (SD) 
Adjusted *,  
mean, (CI95%) 
No symptom,    -34 (29) ref Normal lung 
function† with symptom‡  -37 (30) § -3.6 (-5.2 ; -2.1) § 
  
  
No symptom     -38 (36) -3.1 (-6.6 ;+0.5) 
Stage 1 COPD† 
with symptom‡    -44 (38) § -8.9 (-13.1  ; -4.6) § 
  
  
No symptom       -25 (43) -12.8 (-23.7 ; -1.9) § 
Stage 2-4 COPD† 
with symptom‡    -29 (39) -9.0 (-17.3 ; -0.70) § 
 
  Respiratory care utilization   
 
 Users, % 
Unadjusted OR 
(CI95%) 
Adjusted OR* 
(CI95%) 
No symptom,    7.3 ref ref Normal lung 
function† with symptom‡  14.7 2.18 (1.84 2.58) § 1.86 (1.53 2.26) § 
  
   
No symptom     8.1 1.12 (0.73 1.74) 1.05 (0.63 1.73) Stage 1 COPD† 
with symptom‡    12.5 1.81 (1.20 2.75) § 1.62 (1.01 2.61) § 
  
   
No symptom       23.4 3.86 (1.64 9.07) § 4.05 (1.59 10.30) § Stage 2-4 COPD† 
with symptom‡    34.4 6.65 (3.86 11.45) § 5.67 (2.86 11.22) § 
†: pre-bronchodilator spirometry. *adjusted for age, age squared, gender, baseline FEV1, smoking 
status, lifetime smoking (pack/yr), baseline BMI, weight change, education level, nationality and 
study area (random effect). ‡: report of chronic cough or phlegm or shortness of breath while 
walking. §:P<.05 vs the reference category “Normal lung function, no symptom”  
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Table D (cont.d): Unadjusted and adjusted long-term outcomes associated with modified 
GOLD† and symptom categories 
 
  SF 36 Physical Component Summary  
 
 
Unadjusted, 
mean (SD) 
Adjusted *,  
mean, (CI95%) 
No symptom,    53.1 (6.7) ref Normal lung 
function† with symptom‡  50.6 (9.1) § -1.6 (-2.0 -1.1) § 
  
  
No symptom     51.2 (8.2) § -0.2 (-1.3 0.8) Stage 1 COPD† 
with symptom‡     48.7 (10.8) § -1.6 (-2.9 -0.4) § 
  
  
No symptom        51.4 (4.4) 0.6 (-2.6 3.8) Stage 2-4 COPD† 
with symptom‡       44.2 (12.1) § -5.2 (-7.8 -2.5) § 
 
  SF 36 Mental Component Summary  
 
 
Unadjusted, 
mean (SD) 
Adjusted *,  
mean, (CI95%) 
No symptom,    51.5 (7.7) ref Normal lung 
function† with symptom‡  48.7 (9.4) § -2.6 (-3.2 -2.1) § 
  
  
No symptom     52.5 (7.6) § 0.1 (-1.1 1.3) 
Stage 1 COPD† 
with symptom‡     48.9 (10.1) § -3.1 (-4.5 -1.6) § 
  
  
No symptom        53.9 (6.3) 1.2 (-2.4 4.7) Stage 2-4 COPD† 
with symptom‡       50.5 (9.8) -2.1 (-4.9 0.8) 
 
†: pre-bronchodilator spirometry. *adjusted for age, age squared, gender, baseline FEV1, smoking 
status, lifetime smoking (pack/yr), baseline BMI, weight change, education level, nationality and 
study area (random effect). ‡: report of chronic cough or phlegm or shortness of breath while 
walking. §:P<.05 vs the reference category “Normal lung function, no symptom”  
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Table E (online supplement): Sensitivity analysis including subjects with physician diagnosed asthma. Adjusted FEV1 decline 
difference*, respiratory care utilization and quality of life over 11 years, stratified by modified GOLD† and symptom 
categories at SAPALDIA 1 (1991) 
 
 
 
FEV1 decline 
(ml/year) mean, 
(CI95%) n= 5759 
Respiratory care 
utilization, OR 
(CI95%) n=6051 
PCS mean, (CI95%) 
n= 5172 
MCS mean, (CI95%) 
n= 5172 
No symptom,    ref ref ref ref Normal lung 
function† with symptom‡  -3.6 (-5.1 , -2.0) 2.1 (1.7 , 2.5) -1.6 (-2.1 , -1.2) -2.7 (-3.2 , -2.2) 
  
    
No symptom     -3.1 (-6.5 , +0.4) 1.2 (0.8 , 1.9) -0.1 (-1.2 , +0.9) -0.2 (-1.3 , 1.0) Stage 1 COPD† 
with symptom‡   -11.2 (-15.2 , -7.3) 2.5 (1.7 , 3.7) -1.9 (-3.1 , -0.7) -2.8 (-4.1 , -1.5) 
  
    
No symptom       -12.6 (-22.9 , -2.4) 4.1 (1.8 , 9.5) +0.7 (-2.3 , 3.7) +0.8 (-2.5 , 4.1) Stage 2-4 COPD† 
with symptom‡   -8.4 (-15.4 , -1.4) 9.6 (5.5 , 16.7) -5.3 (-7.6 , -3.1) -3.2 (-5.7 , -0.8) 
*adjusted for age, age squared, gender, baseline FEV1, smoking status, lifetime smoking (pack/yr), baseline BMI, weight change, education level, 
nationality and study area (random effect). †: one or more symptoms = report of chronic cough or phlegm or shortness of breath while walking.  
†: pre-bronchodilator spirometry, ‡: report of chronic cough or phlegm or shortness of breath while walking. see online supplement for detailed 
questions 
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Table F: Sensitivity analysis for emergency room visit or hospitalization for respiratory 
during the year preceding SAPALDIA 2, stratified by modified GOLD† and symptom 
categories at SAPALDIA 1 (1991) 
  Emergency room visit or hospitalizations    
 
 
n, (%) 
Unadjusted OR 
(CI95%) 
Adjusted OR* 
(CI95%) 
No symptom    28 (0.8) ref ref Normal lung 
function† with symptom‡  39 (1.6) 2.1 (1.3 – 3.4) 1.9 (1.1 –3.5) 
  
   
No symptom     5 (1.7) 2.2 (0.8 – 5.8) 0.8 (0.2 – 3.7) Stage 1 COPD† 
with symptom‡    7 (3.1) 4.1 (1.8 – 9.6) 2.8 (1.0 – 8.0) 
  
   
No symptom       0 - - Stage 2-4 COPD† 
with symptom‡    6 (9.8) 14.0 (5.6 – 35.2) 4.7 (1.2 –18.2) 
†: pre-bronchodilator spirometry. *adjusted for age, age squared, gender, baseline FEV1, smoking 
status, lifetime smoking (pack/yr), baseline BMI, weight change, education level, nationality and 
study area (random effect). ‡: report of chronic cough or phlegm or shortness of breath while 
walking. §:P<.05 vs the reference category “Normal lung function, no symptom”  
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